Compliance Study Comparing DuoTrav to TRAVATAN Plus Timolol Using the Dosing Aid
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 81
- 试验地点
- 1
- 主要终点
- Patient compliance
研究概览
简要总结
The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with open-angle glaucoma or ocular hypertension;
- •Other protocol-defined inclusion criteria may apply.
排除标准
- •Visual acuity worse than 0.60;
- •Other protocol-defined exclusion criteria may apply.
研究组 & 干预措施
Travatan/Timolol
One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
干预措施: Timolol maleate ophthalmic solution, 0.5% (Drug)
DuoTrav
One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
干预措施: Travoprost 0.004%/timolol 0.5% ophthalmic solution (Drug)
Travatan/Timolol
One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
干预措施: Travoprost ophthalmic solution, 0.004% (Drug)
结局指标
主要结局
Patient compliance
时间窗: 12 months
Patient compliance will be measured with a dosing aid that records time and date of study drug administration
次要结局
未报告次要终点